We are dedicated to providing widespread access to Praxbind in the rare cases where a patient would potentially need urgent intervention, although we do not expect high volume use.” "The availability of a specific reversal agent for Pradaxa helps provide healthcare providers, patients, and caregivers increased assurance in their anticoagulation treatment decisions. Related: Post-MI NSAID/anticoag combo may increase risk of CV bleeding eventsĪccording to the manufacturer in a company statement: "Praxbind is the first and only specific reversal agent available for a noval oral anticoagulant (Pradaxa). Praxbind is available as an intravenous injection and is indicated for patients treated with Pradaxa, when reversal of the anticoagulant effect is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. Praxbind is the first reversal agent approved specifically for Pradaxa and works by binding the drug to neutralize its blood-thinning effects without interfering with the coagulation cascade. Related: Dabigatran etexilate (Pradaxa): An oral direct thrombin inhibitor
Pradaxa is an anticoagulant that was approved by FDA in 2010 to prevent storke and systemic blood clots in patients with atrial fibrillation, as well as for the treatment and prevention of deep venous thrombosis and pulmonary embolism. FDA has approved idarucizumab (Praxbind, Boehringer Ingelheim) as the first reversal agent for Pradaxa.
0 kommentar(er)
